Peptide Library

Human study PLS-00094

The Relationship Between MOTS-c K14Q Polymorphism and Sarcopenia, Blood Lipids, and Mental Health in Older Korean Adults.

Cross-sectional study · 683 participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • The Relationship Between MOTS-c K14Q Polymorphism and Sarcopenia, Blood Lipids, and Mental Health in Older Korean Adults.primary · Biomedicines · 2024-10-18 · PMID 39457696 · DOI

Design and participants

Design
Cross-sectional study
Population
Community-dwelling Korean adults aged 65 years and older (345 men, 338 women), genotyped for the m.1382A>C polymorphism.
Conditions
Sarcopenia, Blood lipids, Mental health
Setting
Community-dwelling older adults (South Korea)
Planned enrollment (registry)
Not reported
Enrolled
683
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors concluded that the m.1382A>C (MOTS-c K14Q) polymorphism may serve as a genetic biomarker of age-related sarcopenia in older Korean men. No genotype differences were seen in women.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Genotype association study: no MOTS-c was administered, so it gives no evidence on effects of giving the compound.
    • confounding: Observational cross-sectional comparison of genotype groups; residual confounding is possible despite covariate adjustment.
    • abstract only: Only the abstract is available in the record; methods and group sizes by genotype are not fully reported.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 39457696, abstract (Conclusions, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 39457696, abstract (Methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 39457696, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 39457696, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).